Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jan;15(1):50-6.
doi: 10.1111/hiv.12047. Epub 2013 Jun 3.

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

C D Zorrilla  1 , R Wright, O O Osiyemi, S Yasin, B Baugh, K Brown, B Coate, P Verboven, J Mrus, R Falcon, T N Kakuda
Affiliations
Clinical Trial

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

C D Zorrilla et al. HIV Med. 2014 Jan.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] HIV Med. 2019 Aug;20(7):496-499. doi: 10.1111/hiv.12786. HIV Med. 2019. PMID: 31318137 Free PMC article. No abstract available.

Abstract

Objectives: Antiretroviral therapy during pregnancy is recommended to reduce the risk of mother-to-child transmission of HIV and for maternal care management. Physiological changes during pregnancy can affect pharmacokinetics, potentially altering pharmacological activity. We therefore evaluated the pharmacokinetics of twice-daily (bid) darunavir in HIV-1-infected pregnant women.

Methods: HIV-1-infected pregnant women receiving an antiretroviral regimen containing darunavir/ritonavir 600/100 mg bid were enrolled in this study. Total and unbound darunavir and total ritonavir plasma concentrations were obtained over 12 h during the second and third trimesters and postpartum. Total darunavir and ritonavir plasma concentrations were determined using a validated high-performance liquid chromatography tandem mass spectrometry assay and unbound darunavir was determined using (14) C-darunavir-fortified plasma. Pharmacokinetic parameters were derived using noncompartmental analysis.

Results: Data were available for 14 women. The area under the plasma concentration-time curve from 0 to 12 h (AUC12h) for total darunavir was 17-24% lower during pregnancy than postpartum. The AUC12h for unbound darunavir was minimally reduced during pregnancy vs. postpartum. The minimum plasma concentration (Cmin) of total and unbound darunavir was on average 43-86% and 10-14% higher, respectively, during pregnancy vs. postpartum. The antiviral response (< 50 HIV-1 RNA copies/mL) was 33% at baseline and increased to 73-90% during treatment; the percentage CD4 count increased over time. One serious adverse event was reported (increased transaminase). All 12 infants born to women remaining in the study at delivery were HIV-1-negative; four of these infants were premature.

Conclusions: Total darunavir exposure decreased during pregnancy. No clinically relevant change in unbound (active) darunavir occurred during pregnancy, suggesting that no dose adjustment is required for darunavir/ritonavir 600/100 mg bid in pregnant women.

Keywords: HIV; darunavir; pharmacokinetics; pregnancy; ritonavir.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean (standard deviation) plasma concentration–time curves for total darunavir (a), unbound darunavir (b) and total ritonavir (c) after administration of darunavir/ritonavir 600/100 mg twice daily (bid), during the second and third trimesters and postpartum.
See this image and copyright information in PMC

References

    1. Capparelli EV, Best BM, Stek A, et al. Pharmacokinetics of darunavir once or twice daily during and after pregnancy. Rome, Italy, July 15–16, 2011. Poster P72 3rd International Workshop on HIV Pediatrics.
    1. Furco A, Gosrani B, Nicholas S, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS. 2009;23:434–435. - PubMed
    1. Ivanovic J, Bellagamba R, Nicastri E, et al. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS. 2010;24:1083–1084. - PubMed
    1. Jaworsky D, Thompson C, Yudin MH, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther. 2010;15:677–680. - PubMed
    1. Pacanowski J, Bollens D, Poirier JM, et al. Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient. AIDS. 2009;23:1923–1924. - PubMed

Publication types

MeSH terms